Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005605 | 1.00 | KMT2A (0.68) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL9624386 | 0.85 | KMT2A (0.68) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL22638587 | 0.84 | KMT2A (0.49) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL28002534 | 0.84 | KMT2A (0.66) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL13801044 | 0.84 | KMT2A (0.66) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL30006537 | 0.84 | KMT2A (0.66) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL2556706 | 0.83 | ALDH1A1 (0.48) | KMT2ATSHRALDH1A1MAPTALOX15 | |
| Hydrochloric Acid SCHEMBL30004917 | 0.82 | KMT2A (0.64) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30006002 | 0.82 | KMT2A (0.64) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL647372 | 0.81 | KMT2A (1.00) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085848-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025054132-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2022220725-A1 | LPXH INHIBITORS AS ANTI-INFECTIVE AGENTS | ZAMARATSKI EDOUARD (SE) | 2022-10-20 | — | — | WO | disclosed |
| US-10188754-B2 | Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2018-10-18 | — | — | US | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2008135488-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-20020045551-A1 | 4-benzoyl isoxazoles derivatives and their use as herbicides | MUSIL TIBOR (GB) | 2002-04-18 | — | — | US | disclosed |
| US-6323155-B1 | EXCELLENT LEVEL OF HERBICIDAL ACTIVITY TOGETHER WITH CROP TOLERANCE | RHONE-POULENC AGRICULTURE LIMITED (GB) | 2001-11-27 | — | — | US | disclosed |
| EP-0674629-B1 | 4-BENZOYL ISOXAZOLES DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE POULENC AGRICULTURE (GB) | 1998-07-08 | — | — | EP | disclosed |
| EP-0674629-A1 | 4-BENZOYL ISOXAZOLES DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014782-A1 | 4-BENZOYL ISOXAZOLES DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | KMT2A 3648/4885TSHR 3983/4885L3MBTL1 4437/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | KMT2A 3648/4885TSHR 3983/4885L3MBTL1 4437/4885 |
| US-10188754-B2 | Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) | GART, SLC43A1, AADAT | KMT2A 904/4885TSHR 3551/4885L3MBTL1 2470/4885 |
| US-20020045551-A1 | 4-benzoyl isoxazoles derivatives and their use as herbicides | CBR3, CBR1, GLRA3 | KMT2A 3499/4885TSHR 174/4885L3MBTL1 2099/4885 |
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | KMT2A 3648/4885TSHR 3983/4885L3MBTL1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.